Nanjing Pharmaceutical Group Company Limited Class A

Nanjing Pharmaceutical Group Company Limited Class A

SSSE:600713
5.19
CNY
-0.04
(-0.76%)
0.57EPS
10.17P/E
6.54BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
27.85
31.17
27.71
29.79
32.1
30.79
35.66
38.19
43.32
40.05
41.27
41.22
42.22
42.79
Basic EPS, GAAP
0.06
0.18
0.18
0.2
0.26
0.26
0.33
0.36
0.49
0.48
0.45
0.44
0.48
0.49
Free Cash Flow per Basic Share
-0.73
-0.7
-0.53
-0.49
0.08
-0.67
0.68
-1.34
0.37
-0.67
1.35
1.22
-0.12
- -
Dividend per Share
0.34
0.33
0.2
0.16
0.41
0.36
0.48
0.34
0.9
0.39
0.45
0.39
0.38
0.45
Book Value per Share
1.52
2.39
2.56
2.93
3.13
3.53
3.85
4.09
4.42
4.58
4.91
5.22
5.49
5.55
Tangible Book Value per Share
0.96
2.17
2.36
2.71
2.91
3.33
3.54
3.75
4.1
4.34
4.69
4.99
5.24
5.05
Basic Weighted Avg Shares
691
708
896
897
897
1,017
1,042
1,043
1,042
1,254
1,298
1,303
1,302
1,297
Sales/Revenue/Turnover
19,236
22,076
24,813
26,721
28,810
31,303
37,156
39,817
45,123
50,222
53,590
53,696
54,963
55,515
Operating Margin (%)
1.57
1.98
2.11
2.21
2.4
2.58
2.7
2.81
2.95
2.99
2.83
2.96
2.79
2.88
Depreciation Expense
89
84
82
80
87
97
125
136
241
260
270
269
274
- -
Net Income, GAAP
39
129
157
180
232
264
347
376
505
596
578
571
625
638
Effective Tax Rate (%)
49.34
25.3
28.92
29.78
29.73
27.32
26.72
30.65
27.22
20.98
27.12
25.94
28.07
29.9
Profit Margin (%)
0.2
0.58
0.63
0.67
0.81
0.84
0.93
0.95
1.12
1.19
1.08
1.06
1.14
1.15
Working Capital
162
1,429
1,590
1,710
1,937
2,558
2,625
3,901
5,933
6,978
7,447
10,714
9,891
10,712
LT Debt
9
- -
- -
- -
50
63
9
1,208
2,753
2,325
2,237
5,455
4,338
5,332
Total Equity
1,339
2,437
2,687
3,069
3,285
4,121
4,520
4,820
5,234
6,695
7,255
7,788
8,253
8,759
Return on Invested Capital (%)
1.4
2.52
3.51
5.22
4.46
4.42
5.19
4.96
5.35
6.13
5.69
5.09
5.52
- -
Return on Capital (%)
3.37
6.26
5.48
5.7
5.72
5.62
7.92
5.71
6.28
6.14
5.56
4.29
4.21
- -
Return on Common Equity (%)
3.77
8.07
7.06
7.32
8.56
8.15
9.02
9.1
11.4
11.23
9.29
8.6
8.91
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5,261
4,946
3,956
LT Borrowings
4,113
4,641
5,150
LT Finance Leases
177
178
182
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,309
1,308
1,308
Market Capitalization
6,911
6,541
6,541

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
32,465
33,249
34,974
Cash, Cash Equivalents & STI
2,223
3,087
2,005
Accounts Receivable, Net
16,583
17,427
18,709
Inventories
7,098
6,838
7,238
Total Current Liabilities
22,431
22,901
24,262
Payables & Accruals
- -
- -
- -
ST Debt
5,261
4,946
3,956
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.12%
11.64%
5.97%
Free Cash Flow
-253.43%
-174.19%
-110.03%
Net Income, GAAP
15.48%
11.47%
9.5%
Sales/Revenue/Turnover
8.39%
6.78%
2.36%
Total Cash Common Dividend
26.24%
24.37%
-2.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,953
13,280
13,706
12,758
53,696
2025
14,247
13,721
- -
13,828
54,963
2026
13,844
13,979
13,864
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.12
0.1
0.1
0.44
2025
0.14
0.09
- -
0.17
0.48
2026
0.14
0.09
0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.24
0.04
0.03
0.39
2025
0.11
0.18
- -
0.04
0.38
2026
0.08
0.21
0.13
- -
- -

Company Description

CEO
Liang Zhang
Full Time Employees
4,697
Sector
Distribution services
Industry
Medical distributors
Address
Building A Nanjing JS China 210012
IPO Date
Jul 1, 1996
Website
njyy.com
Business
NanJing Pharmaceutical Company Limited operates primarily in pharmaceutical manufacturing, focusing on chemical generic drugs including pharmaceutical active pharmaceutical ingredients (APIs), biological products, and plasma products. Its product portfolio covers a wide range of therapeutic segments such as antidiabetic, cardiovascular, central nervous system, antifungal, neuromuscular blockade reversal, and antiepileptics. Key pharmaceutical products include Apremilast, Indacaterol, Sugammadex Sodium, Posaconazole, Amphotericin B, Brivaracetam, Liraglutide, Empagliflozin, Dapagliflozin, and Canagliflozin. The company also produces human fibrinogen derived from purified plasma. NanJing Pharmaceutical exports its products to nearly 60 countries and integrates its business across four major sectors: pharmaceutical international trading, technology transfer, regulatory affairs consultation, and supply chain and sales channel integration. The company emphasizes high-quality standards with several branded APIs recognized with national and provincial awards for quality and innovation. Its manufacturing facilities in Nanjing are equipped with advanced testing equipment and comply with regulatory certifications including local GMP and DMF certifications. Recent major company changes include a strategic move towards capital operations and expansion through acquisitions, notably signing a letter of intent to acquire asset groups from Future Pharmaceutical to enrich its product pipelines and support its "big health" strategy, focusing on an all-age health management product matrix and optimizing product lines in anti-infection, chronic disease, and nutritional support. NanJing Pharmaceutical also advanced its digital transformation by capital increase in its wholly-owned subsidiary Zhongjian Information to enhance competitiveness. In 2025, the company completed a significant equity buyback and obtained approval for a restricted stock incentive plan. Additionally, it plans to issue medium-term notes up to 5 billion yuan to optimize debt structure and broaden financing channels. It has expanded its operations through leasing factory buildings in Nanjing for warehousing and office use to support business growth. Founded in 1958 and headquartered in Nanjing, Jiangsu Province, China, NanJing Pharmaceutical serves both domestic and international markets, targeting healthcare providers, pharmaceutical distributors, and government health sectors. It maintains a nationwide marketing network and focuses on innovation in drug research and clinical development, including advancing Phase III trials for new drug candidates to enhance its product pipeline and commercial offerings. The company is publicly listed on the Shanghai Stock Exchange under the ticker 600713.SS.